Gilead Licenses Obeldesivir for Potential Supply in 127 Countries
Gilead signed royalty-free licensing agreements with three generic manufacturers covering 127 primarily low- and lower-middle-income countries. Supply is contingent on clinical data and regulatory authorization; obeldesivir remains investigational.
Story updates
09:06:03 PM UTC
SquawkNews
GILEAD - SIGNS ROYALTY-FREE VOLUNTARY LICENSING AGREEMENTS FOR OBELDESIVIR AS PEP FOR EBOLA BVD
09:06:07 PM UTC
SquawkNews
GILEAD - AGREEMENTS COVER 127 LOW- AND LOWER-MIDDLE-INCOME COUNTRIES INCLUDING ALL AFRICAN COUNTRIES